Core Viewpoint - The article highlights the upcoming Second Global Medical Technology Conference organized by Suyu MedTech, scheduled for July 17, 2025, in Beijing, focusing on "Cutting-edge Technology: From R&D to Clinical Application" [1][6]. Conference Overview - The conference will take place at the Zhongguancun Exhibition Center in Haidian District, Beijing [6]. - The event is expected to attract approximately 500 participants from various sectors, including government, hospitals, leading enterprises, startups, investment institutions, and research institutes [8]. - A significant awards ceremony will showcase and honor global medical technology innovations on the main stage [8]. Key Topics of Discussion - The conference will address several critical topics, including: - AI and intelligent systems [7] - Challenges in the implementation of medical AI and large models [9] - Upgrades in imaging equipment and platforms [10] - Innovations in high-value consumables and interventional techniques [11] - Energy platforms and intraoperative devices [12] - Innovations in materials and structural optimization [13] Roundtable Discussions - A roundtable discussion will focus on how innovative products can effectively enter clinical settings and be utilized [14]. Registration Information - Interested parties can register for the conference by copying the provided link or scanning the QR code [15].

Core Viewpoint - The article emphasizes the collaboration between doctors, CEOs, engineers, and investors to address challenges in medical device innovation through a workshop organized by Shanghai Jiao Tong University School of Medicine and its affiliated institutions [1]. Training Information - The workshop titled "Medical Device Innovation and Engineering Transformation Workshop" aims to merge medical pain points with engineering technology to create innovative medical products and facilitate results transformation [5]. - The workshop will take place on August 16-17, 2025, at Shanghai Jiao Tong University School of Medicine, with a fee of 8999 yuan per person, covering course materials and refreshments [10]. Course Highlights - Participants will learn the Biodesign innovation methodology, which is a global leading model for medical engineering innovation, focusing on demand discovery and creative generation from clinical needs [6]. - The workshop will provide insights into the trends of the medical device industry, enabling participants to seize market opportunities [6]. - Networking opportunities will be available, allowing participants to connect with doctors, researchers, industry experts, and investors to support their career development [6]. Course Structure - The first day will cover medical innovation and technology layout, followed by practical innovation exercises and team drills to foster interdisciplinary collaboration [7][9]. - The second day will focus on the industrialization of innovation and team building, including discussions on funding sources and investment opportunities in the medical engineering sector [13][16]. Expert Faculty - The workshop features a team of distinguished faculty members from Shanghai Jiao Tong University, including experts in biomedical engineering and medical technology innovation, who will share their knowledge and experiences [14][17].

未来，随着人工心脏技术与个体化治疗管理模式不断融合，该类装置有望为更多终末期心衰患者带来生存 可能与生活质量的提升。 # 病情危重，人工心脏介入成唯一可行路径 思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 | 首届全球医美科技大会 即将召开： 2025年7月17日，第二届全球医疗科技大会 2025年9月3-5日，第三届全球手术机器人大会 心未来 近日， 上海瑞金医院心脏外科 的一项面向终末期心衰患者的高难度手术取得重要进展——一名58岁女性 患者在 心脏持续跳动状态下 成功植入了 深圳核心医疗科技股份有限公司 （以下简称" 核心医疗 "）自 主研发 DuoCor™双心室辅助装置 。 手术完成2个月后，患者恢复良好，心功能显著改善。 DuoCor ™解决了左心室辅助装置只能提供单心循环支持的局限，拓展了人工心脏的适用范围，将为心衰 患者带来效果更优、风险更低、可长期获益的临床解决方案，在心衰发病率攀升的背景下，将迎来更为广 阔的发展前景。 患者张女士（化名）长期饱受心力衰竭困扰，近年来病情不断恶化，出现反复晕厥和下肢水肿。在被多家 医院确诊为 "终末期心衰"后，转至 上海 ...

Core Viewpoint - The article discusses the strategic advancements and challenges faced by Shanghai United Imaging Healthcare Co., Ltd. (United Imaging) in the field of AI-driven medical technology, emphasizing its recent A-round financing and the broader implications for the medical AI industry [1][3]. Financing Insights - United Imaging successfully completed an A-round financing of 1 billion RMB, marking a significant investment in AI technology despite the current market's conservative sentiment [1][3]. - This financing reflects a long-term strategic commitment from United Imaging and its investors, recognizing AI capabilities as a core competitive advantage [3]. AI Development Strategy - Founded in late 2017, United Imaging has focused on embedding AI into clinical settings, starting with diagnostic tools and expanding to over 100 products across various medical fields [4][7]. - The company has achieved significant regulatory milestones, including 22 NMPA Class II certifications and 12 Class III certifications, along with FDA and CE approvals for several applications [4]. Business Model Challenges - Despite rapid product development, United Imaging reported revenues of 254 million RMB and a loss of 136 million RMB in 2023, highlighting the ongoing struggle to establish a clear commercial model in the medical AI sector [11][12]. - Key challenges include hospitals' reluctance to pay for software, especially in a cost-controlled environment, and the need for comprehensive solutions that address multiple disease types rather than single-function products [12][13]. Technological Innovations - United Imaging is developing a multi-modal AI platform, uAI, which integrates various data types to enhance clinical workflows and improve diagnostic accuracy [14][17]. - The company aims to create a "smart ecosystem" where AI acts as a self-evolving system, enhancing efficiency across all hospital processes [18][20]. Future Outlook - The medical AI industry is shifting from a focus on model parameters to ecosystem strength, with United Imaging positioning itself as a platform company rather than a tool provider [22][23]. - The company faces high costs associated with continuous model iteration and the integration of AI into clinical settings, but its comprehensive approach may provide a sustainable competitive edge in the long term [24][25].

Core Viewpoint - The article discusses the establishment of the first Orthopaedic Ambulatory Surgery Centre (ASC) in the UK by Smith+Nephew in collaboration with Standard Health, aimed at alleviating the pressure of long waiting times for orthopaedic surgeries within the NHS and enhancing healthcare efficiency [1][2][4]. Group 1: Collaboration Details - Smith+Nephew will provide innovative medical technology products for the Poole ASC, focusing on orthopaedics, sports medicine, and advanced wound management [2]. - The centre is expected to open in 2025 and will serve thousands of patients, primarily through NHS referrals, while also accepting private patients [2]. - The ASC will offer a variety of orthopaedic surgical services, including rotator cuff repair, ACL reconstruction, knee and hip replacements, and surgeries for the foot, ankle, and wrist [2]. Group 2: ASC Model - The ASC model is based on a successful American framework, with over 6,000 ASCs in the U.S. accounting for more than 50% of outpatient surgeries, known for efficiency, lower costs, and higher patient satisfaction [5]. - The Poole ASC will introduce features such as streamlined processes and specialized surgical environments, reducing surgery time and hospital costs, with ASC surgery costs being 45-60% lower than hospital outpatient department (HOPD) costs [5]. - Patient satisfaction is expected to be higher due to personalized care experiences and reduced waiting times and infection risks [5]. Group 3: Market Outlook - The NHS in the UK faces significant challenges with long waiting times for orthopaedic surgeries, with over 850,000 patients waiting for procedures as of June 2025 [6]. - The ASC market in the U.S. performed nearly 23 million surgeries in 2020, indicating a significant shift in patient preference towards more convenient care options [6]. - The ASC market is projected to reach approximately $97 billion by 2026, with a compound annual growth rate (CAGR) of 5.6% from 2021 to 2026 [6]. Group 4: Company Overview - Smith+Nephew, founded in 1856 and headquartered in Hull, UK, is a leading global orthopaedic medical device company focusing on joint repair, sports medicine, wound management, and neuroscience [10]. - The company reported revenues of $5.81 billion and an operating profit of $657 million in 2024, employing over 18,000 people globally [10]. - Key products include the JOURNEY II knee replacement system and the CORI surgical robot system, with innovations like the TESSA spatial surgery system aimed at improving surgical outcomes [10][11].

思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 | 首届全球医美科技大会 即将召开： 2025年7月17日，第二届全球医疗科技大会 2025年9月3-5日，第三届全球手术机器人大会 2025年6月， 瑞士神经影像设备开发公司 Positrigo 宣布 ，旗下NeuroLF脑部PET系统 继2024年获得美国FDA 和欧盟CE双重认证后，已完成一轮新融资 （具体金额与投资方未公开），旨在加速其在欧美市场的商业化部 署。 Positrigo AG 是一家总部位于 瑞士苏黎世 的医疗影像设备公司，成立于2018年，专注于开发 专用于脑部疾病 诊断的紧凑型PET成像系统 。公司最初由苏黎世联邦理工学院（ETH Zurich）的研究人员孵化而来，聚焦神 经退行性疾病早期诊断中的影像技术瓶颈，尤其是在阿尔茨海默病等疾病领域。 Positrigo的融资案例亦映射出脑科学器械赛道的资本回暖。2025年1月，Klotho Neurosciences亦完成针对阿尔茨 海默病的早期设备融资；美国及欧洲市场正成为神经成像创新集中试点区。 该事件不仅标志着Positrigo向全球神经功能影像领域迈出 ...

Core Insights - Medtronic's VitalFlow ECMO system has received CE certification, marking a significant milestone in ECMO innovation and patient care [2][4][30] - The VitalFlow system is designed to be a compact, user-friendly, and integrated ECMO platform, catering to acute rescue, bedside treatment, and intra-hospital transport needs [4][28] - The acquisition of MC3 Cardiopulmonary by Medtronic has facilitated the development of the VitalFlow system, enhancing its capabilities and market positioning [16][30] Group 1: Product Development and Features - VitalFlow is a result of Medtronic's acquisition of MC3 Cardiopulmonary, which was completed in March 2024, and focuses on integrating ECMO system components [7][16] - The system includes a centrifugal pump, a plasma-sealed PMMA hollow fiber oxygenator, and a user-friendly touch interface for real-time monitoring [10][11] - VitalFlow is positioned as an "end-to-end" solution in the acute-chronic continuum of care, supporting preoperative, intraoperative, and postoperative monitoring [22][30] Group 2: Market Positioning and Competition - The global ECMO market includes competitors like Getinge's Cardiohelp and LivaNova's SCPC, each with distinct technical approaches and application scenarios [23][27] - VitalFlow fills a market gap by offering a balance of moderate support intensity, user-friendliness, and high integration, making it suitable for rapid deployment across various hospital departments [28][29] - The competitive landscape is shifting from device performance to platform collaboration, emphasizing the integration of core modules and process optimization [30]

Core Insights - The article highlights the successful approval of SkuHeal™ artificial bone repair material by the Vietnamese Ministry of Health, following its previous registrations in China and Indonesia [1][3] - The company, Aojing Medical Technology Co., Ltd., specializes in high-end biomedical materials and has developed a series of mineralized collagen artificial bone repair materials [8] Company Overview - Aojing Medical was established on December 22, 2004, and was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on May 21, 2021 [8] - The company focuses on the research, production, and sales of biomedical materials, with key products including "Gaojin," "Chibei," and "Curu" [8] - Aojing Medical's products have been clinically applied in over 600 hospitals in China, with more than one million cases, and have received FDA 510(k) market access approval [8] Product Details - SkuHeal™ is developed using proprietary in vitro biomimetic mineralization technology, closely mimicking the composition and microstructure of natural bone tissue [6] - The product is primarily used for bone defect repair in neurosurgery, including fractures, non-union, and bone defects, demonstrating significant potential for clinical application [7] - Other key products include Gaojin for orthopedic bone defect repair, Chibei for oral or plastic surgery, and Curu for neurosurgery [9]

Core Viewpoint - The second Global Medical Technology Conference organized by Suyu MedTech will take place on July 17, 2025, in Beijing, focusing on "Cutting-edge Technology: From R&D to Clinical Application" [1][6]. Group 1: Conference Overview - The conference will be held at the Zhongguancun Exhibition Center in Haidian District, Beijing [6]. - The expected attendance is approximately 500 participants, including representatives from government, hospitals, leading enterprises, startups, investment institutions, and research institutes [8]. - The agenda will feature discussions on product innovation, technology implementation, and collaboration between medicine and engineering [6][8]. Group 2: Key Topics of Discussion - The conference will emphasize the challenges of implementing medical AI and large models, including multi-modal data integration and embedding solutions into doctors' workflows [9]. - Topics will also cover advancements in imaging equipment, high-value consumables, energy platforms, and material innovations [10][11][12][13]. - A roundtable discussion will focus on how innovative products can effectively enter clinical settings and be utilized [14]. Group 3: Participation and Opportunities - Companies interested in participating can secure exhibition space, which offers branding exposure and business collaboration opportunities [1]. - Registration methods include a link for online registration and a QR code for easy access [15].

Core Viewpoint - The article emphasizes the significance of the Singularity Program, highlighting its comprehensive approach to integrating medical knowledge, investment thinking, cutting-edge technology, and practical industry experience [3][6]. Group 1: Program Structure and Content - The program consists of 18 modules spread over 9 weekends, featuring immersive real-world visits [8][10]. - It covers various medical fields, including cardiovascular health, aesthetics, life sciences, weight management, and more, with a focus on both theoretical foundations and practical applications [14]. - Participants will engage in hands-on experiences, such as simulator operations and real project roadshows, to enhance their presentation and logical reasoning skills [11][13]. Group 2: Expert Involvement - The program is led by a team of senior mentors, including academic leaders, investment experts, technical specialists, and industry pioneers [4][7]. - Participants will have opportunities for one-on-one guidance from field experts and will engage in discussions with senior professionals from various sectors [12][19]. Group 3: Networking and Resources - The program facilitates connections with a global network of health industry innovators, providing priority access to research transformation projects and investment opportunities [12][19]. - It aims to create a comprehensive ecosystem covering the entire medical industry chain, enhancing collaboration among participants [9]. Group 4: Enrollment and Timeline - Enrollment for the program is open until June 30, 2025, with the course running from July to December 2025 [10][18]. - The program is hosted by the Global Health Industry Innovation Center, which focuses on bridging global medical innovation technologies and resources [18].